Dialyze Direct | July 28, 2022
Dialyze Direct, the nation’s leading provider of home hemodialysis services in Skilled Nursing Facilities. announced it has partnered with CommuniCare Family of Companies, one of the nation’s largest post-acute care providers, to conduct onsite hemodialysis services at its facilities around the U.S.
Founded in 1984 on the philosophy of “Serving with Pride,” CommuniCare’s standard of excellence, which focuses on patient care and quality of life, mirrors Dialyze Direct’s mission to change the dialysis industry by pioneering customized, gentler care proven to positively impact patients’ prognoses and quality of life. Dialyze Direct’s continued growth with like-minded healthcare providers has further solidified the company’s position as the foremost home hemodialysis provider to SNFs in the United States.
“The ultimate goal of healthcare is to provide services that benefit our clients but also to ensure those services save or significantly prolong lives. As a result, we approach partnerships with the understanding that both parties share a common patient-first philosophy. We are pleased to bring our onsite dialysis offerings to CommuniCare’s facilities and join forces with a fellow provider that also views patient comfort and care as the cornerstone of their business model.”
Dialyze Direct’s Chairman and Co-Founder Henry Kauftheil
Dialyze Direct recently announced its acquisition of Chicago-based RenPro Renal Services, which provided dialysis services to patients in SNFs in Illinois, Indiana, Ohio and Kentucky. Earlier this year, the company completed its acquisition of Compass Home Dialysis, a regional SNF dialysis provider in Pennsylvania, and at the end of 2021, the company acquired Renew Dialysis, a regional SNF dialysis provider in Ohio and Virginia.
“Providing our residents with a better quality of life is what we strive for at CommuniCare,” said Ronald Wilheim, President of CommuniCare. “We are proud to partner with Dialyze Direct and that through this partnership we have another opportunity to raise the bar and innovate our level of care.”
Dialyze Direct now offers onsite dialysis services in more than 170 SNFs in Florida, Illinois, Indiana, Kentucky, Maryland, Missouri, New Jersey, New York, Ohio, Pennsylvania, Tennessee, Texas, Virginia, and West Virginia.
About Dialyze Direct
Founded in 2015, Dialyze Direct is a leading kidney care innovation company that seeks breakthrough solutions for patients suffering from kidney disease. With a mission to build the next generation of kidney care, Dialyze Direct leverages its leading nephrology specialists to develop new methods and technology to evolve the treatment options nephrologists have at their disposal. Dialyze Direct pioneered significant changes to the existing treatment model for dialysis patients in skilled nursing facilities (SNFs), in which many of the most medically challenging subsets of dialysis patients reside, and has grown to become the nation’s largest provider of home dialysis in the SNF setting. Dialyze Direct’s innovative staff-assisted home hemodialysis treatment model entails a gentler, personalized treatment plan comprised of meticulously crafted protocols designed to tackle the unique fluid management challenges of geriatric dialysis patients, resulting in increased overall patient health and reduced hospitalizations while substantially decreasing costs for payors. Dialyze Direct currently operates in 13 states with new operations launching soon in additional states.
About CommuniCare Health Services
CommuniCare Health Services was founded in 1984 and is headquartered in Cincinnati, Ohio. The company currently operates more than 110 healthcare and rehabilitation centers in seven states.
Our centers focus on patient-centered care plans and provide specialized programing in cardiac, pulmonology, memory care & dementia, amputee and behavioral health. Our expert physicians and nurses provide care for the most medically complex residents.
FUTURE OF HEALTHCARE
Quipt Home Medical Corp | July 26, 2022
Quipt Home Medical Corp. a U.S. based leader in the home medical equipment industry, focused on end-to-end respiratory care, is very pleased to announce the execution of a contract with Cardinal Health at-Home, a business unit of Cardinal Health, Inc. wherein Quipt has agreed to offer to sell, and Cardinal has agreed to supply and distribute, disposable medical supplies nationwide. Headquartered in Dublin, Ohio, Cardinal Health, Inc. is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities.
“The execution of this contract with Cardinal Health for the supply of disposable medical supplies is an important milestone for Quipt, and we are thrilled to form this alliance during a period of significant growth. Cardinal will service our entire operating footprint, consisting of 94 locations across the country aimed at increasing distribution channels while decreasing costs. Furthermore, this contract will provide us the ability to expand our continuum of care, produce meaningful cross selling opportunities and allow us to further leverage the national insurance contract recently announced. This contract with Cardinal will also assist us in expanding our presence in the states we serve giving us additional verticals to go after. Additionally, any new acquisitions, will benefit from being able to immediately leverage the contract at new locations across the country, providing further synergies with the expectation this contract will give us stronger buying power for disposable medical supplies. The contract with Cardinal, recent new national insurance contract, and deep acquisition pipeline have us extremely excited about the remainder of 2022 and beyond.”
Greg Crawford, Chairman and CEO of Quipt
ABOUT QUIPT HOME MEDICAL CORP.
The Company provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company’s organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient’s services, and making life easier for the patient.
ABOUT CARDINAL HEALTH
Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities. With 50 years in business, operations in more than 30 countries and approximately 44,000 employees globally, Cardinal Health is essential to care. Cardinal Health at-Home provides Home Medical Equipment and Home Health and Hospice teams with comprehensive solutions to better support their patients in the home.
Sense Biodetection | September 02, 2022
Global molecular diagnostics innovator, Sense Biodetection announced it has entered into a strategic agreement with TECOmedical for the non-exclusive distribution of Sense’s Veros COVID-19, the first test on the rapid, instrument-free, point-of-care Veros molecular testing platform.
The self-contained, single-use Veros COVID-19 product produces PCR-quality results in about 15 minutes, unconstrained by a reader or need for external power. TECOmedical, a Eurobio Scientific Company, is a leading specialty medical distributor with proven success developing new markets with innovative technology. Effective immediately in Germany and Austria, and pending regulatory approval in Switzerland, the agreement is the latest in Sense’s planned EU distribution partnerships as it commercializes its Veros platform.
“We are delighted to partner with TECOmedical to bring Veros COVID-19 to the market, building on the impressive reputation that TECOmedical has established with their customers,” stated Ryan Roberts, Chief Commercial Officer of Sense. “We’re optimistic that by adding the instrument-free Veros COVID-19 to their diagnostic portfolio, TECOmedical’s customers will be able to take advantage of a laboratory-quality molecular test that can enable improved access and faster diagnosis, helping them to provide exceptional care for their patients right at the point of use.”
“We are always looking for innovative technologies that address an unmet need. Being able to offer an instrument free, PCR-quality result in minutes right at the Point of Care reflects our commitment to customers to bring solutions that help them overcome limitations of existing technologies and improve care. We are excited to launch Veros COVID-19 now and are eagerly anticipating an expanded Veros test menu in the future.”
Marieluise Wippermann, CEO of TECOmedical
Veros is the first and only instrument-free, single-use, rapid, point-of-care molecular diagnostic testing platform that produces lab-quality results in about 15 minutes. Using a proprietary, rapid molecular amplification technology, Veros aims to help to improve access to rapid, highly accurate, point of care testing for many more people, and help reduce the spread of COVID-19 with faster, more precise diagnoses.
Veros COVID-19’s clinical performance was established in one of the most comprehensive clinical trials in COVID-19 diagnostic testing conducted to date. The multicentre study prospectively enrolled nearly 300 evaluable subjects during both the Delta and Omicron variant surges of the pandemic. All study sites represented near-patient testing / point-of-care environments, with all test operators reporting no prior formal laboratory training or experience. 100% of operators agreed the Veros COVID-19 was easy-to-use, read and understand the results, with minimal hands-on time required from start to finish.
As the virus continues to evolve, Veros COVID-19 has maintained 100% conservation in all Variants of Interest and Concern identified to date by WHO and the US CDC, including all Omicron sub-variants.
About Sense Biodetection
Sense Biodetection is a global molecular diagnostics company focused on empowering patients and transforming healthcare access and affordability by bringing lab-quality results through easy-to-use, rapid, disposable molecular tests without the constraints of an instrument. The company's Veros product platform will enable widespread testing to enhance patient access, improve patient health and lower systemic healthcare costs. Backed by respected investors, such as Koch Disruptive Technologies, Cambridge Innovation Capital, Earlybird Health and Mercia Asset Management, Sense has launched its first product, Veros COVID-19, and is growing rapidly while building a portfolio of tests for other diseases.
The Swiss-based TECOmedical Group, a Eurobio Scientific company, with subsidiaries in Germany and Austria is a leading provider of in-vitro specialty test systems in medical diagnostic, based on Immunosorbent, Immunofluorescence and Molecular methodologies.